When mice received this AAV-UGI vector before exposure to HSV-1, they were far more likely to survive. However, when the mice lacking APOBEC1 received this treatment, the protective effect ...

When mice received this AAV-UGI vector before exposure to HSV-1, they were far more likely to survive. However, when the mice lacking APOBEC1 received this treatment, the protective effect ...

Once hailed as the solution to delivering gene therapies, adeno-associated virus (AAV) vectors have seen their star dim in recent years ... Meanwhile, Chambon’s company EG 427 has based its genetic ...

卵巢癌死亡率高，免疫检查点抑制剂治疗效果不佳且副作用大。研究人员利用腺相关病毒 - 成簇规律间隔短回文重复序列 / Cas9 ...

Conventional CRISPR nucleases, including Cas9 and Cas12a, exceed the packaging limits of a single AAV vector, necessitating ...

In addition, first-generation CRISPR systems (Cas9 and Cas12a) are too large for efficient in vivo delivery via a single adeno-associated viral (AAV) vector. Now, new preclinical research ...

reminding us that the development of novel anti-HSV-1 agents is necessary. There appears to be no single approach to solving the problem of viral drug resistance, and the development of individual or ...

Researchers from Excision Biotherapeutics Inc. and affiliated organizations have reported the development of a novel CRISPR/Cas9-mediated genome editing therapy – EBT-104 – for the treatment of latent ...

EBT-104 is a CRISPR-based gene therapy that is being developed as a potential cure for HSV-1 Keratitis. EBT-104 utilizes a CRISPR/Cas gene editing system to inactivate the latent HSV-1 virus by co ...

(“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious latent viral infectious diseases, today announced that it will present positive ...